Ranbaxy gets US nod to sell Alzheimer's generic

22 Sep 2010 Evaluate

Ranbaxy may get the final FDA approval to market the drug known under the brand name, Aricept, as soon as patent protection over the drug expires on November 25.Aricept raked in sales of about $3.2 billion globally last fiscal, 60% of which came from the US, the world’s largest pharmaceutical market. 

 

The exclusivity status was confirmed by the US regulator, the Food and Drug Administration (FDA), after it dismissed Israeli drug major Teva’s claim for a shared marketing exclusivity for the drug. The drug will fetch Ranbaxy about $300 million (Rs 1,370 crore) during the exclusivity period.

crackcrack
Peers
Company Name CMP
Sun Pharma Inds. 1769.90
Dr. Reddys Lab 1164.60
Cipla 1517.65
Lupin 2036.55
Zydus Lifesciences 860.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...